The Experts below are selected from a list of 54 Experts worldwide ranked by ideXlab platform

Gerald Wölkart - One of the best experts on this subject based on the ideXlab platform.

  • subcutaneous injection of liquid and foamed polidocanol extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy
    Journal of The European Academy of Dermatology and Venereology, 2011
    Co-Authors: Sanja Schullerpetrovic, N. Neuhold, Friedrich Brunner, M D Pavlovic, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes <0.5 mL regardless of the concentration or form of polidocanol injected. Foam preparation was shown to be less potent in inducing necrosis with a minimal strength being 2% in comparison with the liquid form where 1% was sufficient to produce overt cutaneous necrosis. Conclusions  This experimental study shows that extravasation of polidocal in usual circumstances of sclerotherapy of Spider and reticular Veins cannot be a significant cause of cutaneous necrosis rarely observed in this setting. It is particularly true for the foamed polidocanol where 1% strength seems safe if injected extravascularly in volumes up to 0.5 mL.

  • Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2010
    Co-Authors: S. Schuller-petrović, M.d. Pavlović, N. Neuhold, Friedrich Brunner, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes

Friedrich Brunner - One of the best experts on this subject based on the ideXlab platform.

  • subcutaneous injection of liquid and foamed polidocanol extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy
    Journal of The European Academy of Dermatology and Venereology, 2011
    Co-Authors: Sanja Schullerpetrovic, N. Neuhold, Friedrich Brunner, M D Pavlovic, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes <0.5 mL regardless of the concentration or form of polidocanol injected. Foam preparation was shown to be less potent in inducing necrosis with a minimal strength being 2% in comparison with the liquid form where 1% was sufficient to produce overt cutaneous necrosis. Conclusions  This experimental study shows that extravasation of polidocal in usual circumstances of sclerotherapy of Spider and reticular Veins cannot be a significant cause of cutaneous necrosis rarely observed in this setting. It is particularly true for the foamed polidocanol where 1% strength seems safe if injected extravascularly in volumes up to 0.5 mL.

  • Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2010
    Co-Authors: S. Schuller-petrović, M.d. Pavlović, N. Neuhold, Friedrich Brunner, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes

N. Neuhold - One of the best experts on this subject based on the ideXlab platform.

  • subcutaneous injection of liquid and foamed polidocanol extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy
    Journal of The European Academy of Dermatology and Venereology, 2011
    Co-Authors: Sanja Schullerpetrovic, N. Neuhold, Friedrich Brunner, M D Pavlovic, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes <0.5 mL regardless of the concentration or form of polidocanol injected. Foam preparation was shown to be less potent in inducing necrosis with a minimal strength being 2% in comparison with the liquid form where 1% was sufficient to produce overt cutaneous necrosis. Conclusions  This experimental study shows that extravasation of polidocal in usual circumstances of sclerotherapy of Spider and reticular Veins cannot be a significant cause of cutaneous necrosis rarely observed in this setting. It is particularly true for the foamed polidocanol where 1% strength seems safe if injected extravascularly in volumes up to 0.5 mL.

  • Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2010
    Co-Authors: S. Schuller-petrović, M.d. Pavlović, N. Neuhold, Friedrich Brunner, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes

Margaret Dingui - One of the best experts on this subject based on the ideXlab platform.

  • Prevention or reversal of deep venous insufficiency by aggressive treatment of superficial venous disease.
    American journal of surgery, 2006
    Co-Authors: Imtiaz Ahmad, Waheed Ahmad, Margaret Dingui
    Abstract:

    Abstract Background This study of patients who received either aggressive or less-aggressive treatment for superficial venous disease was undertaken to determine its effects on deep venous insufficiency (DVI). Methods From 1998 to 2004, we treated 1,500 consecutive patients with superficial venous disease at our outpatient care center. A total of 100 patients were available for the study; the remaining patients were not available for the complete follow-up duplex scans 6 months after therapy, irrespective of the therapeutic results. Sixty-four patients underwent aggressive therapy, which included high ligation with partial selective perforation-invagination (PIN) axial stripping of the greater saphenous Vein, ambulatory stab phlebectomy of the varicose Veins, and transdermal treatment of the Spider Veins. Thirty-six patients underwent less-aggressive treatment, which included high ligation with selective partial PIN axial stripping of the greater saphenous Vein and ambulatory phlebectomy of varicose Vein clusters but no Spider Vein treatment. Results Follow-up duplex scanning after aggressive treatment of superficial venous disease showed improvement or complete reversal of DVI in the majority of patients. This improvement was defined as a marked decrease in the size of the deep Veins in 80% of patients and a decrease of the reflux closure time of the deep venous valves in 83% of patients. Only 28% of patients receiving less-aggressive treatment without transdermal laser therapy of the Spider Veins showed improvement in their reflux valve closure time; the remaining 72% were unchanged or deteriorated. Conclusions Aggressive treatment of superficial venous disease can prevent or even eliminate deep Vein insufficiency (DVI).

  • Scientific papers-clinical (American) Prevention or reversal of deep venous insufficiency by aggressive treatment of superficial venous disease
    2006
    Co-Authors: Imtiaz Ahmad, Waheed Ahmad, Margaret Dingui
    Abstract:

    Background:This study of patients who received either aggressive or less-aggressive treatment for superficial venous disease was undertaken to determine its effects on deep venous insufficiency (DVI). Methods:From 1998 to 2004, we treated 1,500 consecutive patients with superficial venous disease at our outpatient care center. A total of 100 patients were available for the study; the remaining patients were not available for the complete follow-up duplex scans 6 months after therapy, irrespective of the therapeutic results. Sixty-four patients underwent aggressive therapy, which included high ligation with partial selective perforation-invagination (PIN) axial stripping of the greater saphenous Vein, ambulatory stab phlebectomy of the varicose Veins, and transdermal treatment of the Spider Veins. Thirty-six patients underwent less-aggressive treatment, which included high ligation with selective partial PIN axial stripping of the greater saphenous Vein and ambulatory phlebectomy of varicose Vein clusters but no Spider Vein treatment. Results:Follow-up duplex scanning after aggressive treatment of superficial venous disease showed improvement or complete reversal of DVI in the majority of patients. This improvement was defined as a marked decrease in the size of the deep Veins in 80% of patients and a decrease of the reflux closure time of the deep venous valves in 83% of patients. Only 28% of patients receiving less-aggressive treatment without transdermal laser therapy of the Spider Veins showed improvement in their reflux valve closure time; the remaining 72% were unchanged or deteriorated. Conclusions:Aggressive treatment of superficial venous disease can prevent or even eliminate deep Vein insufficiency (DVI). © 2006 Excerpta Medica Inc. All rights reserved.

Sanja Schullerpetrovic - One of the best experts on this subject based on the ideXlab platform.

  • subcutaneous injection of liquid and foamed polidocanol extravasation is not responsible for skin necrosis during reticular and Spider Vein sclerotherapy
    Journal of The European Academy of Dermatology and Venereology, 2011
    Co-Authors: Sanja Schullerpetrovic, N. Neuhold, Friedrich Brunner, M D Pavlovic, Gerald Wölkart
    Abstract:

    Background  Cutaneous necrosis is one of the most annoying complications of reticular and Spider Vein sclerotherapy. The precise incidence of the complication is not known, although various sources reported incidence between 0.2% and 1.2%. Among a few mechanisms proposed to explain it, extravasation of the sclerosant into the perivascular tissue has been cited as the major cause. Objectives  The aim of the experimental study in rats was to examine the potential of various concentrations and volumes of polidocanol in both liquid and foam forms to cause cutaneous necrosis after superficial subcutaneous injection. Methods  Twenty-four female Sprague Dawley rats were injected subcutaneously different concentrations (0.5%, 1%, 2% and 3%) of polidocanol as well as different preparations of polidocanol (liquid vs. foam) and volumes (0.1–0.5 mL). The animals were sacrificed 10 days after injections and biopsy specimens were obtained. Results  Cutaneous necrosis was not seen at volumes <0.5 mL regardless of the concentration or form of polidocanol injected. Foam preparation was shown to be less potent in inducing necrosis with a minimal strength being 2% in comparison with the liquid form where 1% was sufficient to produce overt cutaneous necrosis. Conclusions  This experimental study shows that extravasation of polidocal in usual circumstances of sclerotherapy of Spider and reticular Veins cannot be a significant cause of cutaneous necrosis rarely observed in this setting. It is particularly true for the foamed polidocanol where 1% strength seems safe if injected extravascularly in volumes up to 0.5 mL.